Cutler Group LP Glycomimetics Inc Transaction History

Cutler Group LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Oct 28, 2019	BUY	$2.8 - $12.85 $2,520 - $11,565	900 Added 900.0%	1,000 $4,000
Q1 2019 May 10, 2019	BUY	$9.96 - $13.44 $996 - $1,344	100 New	100 $1,000
Q4 2018 Feb 05, 2019	SELL	$8.47 - $14.71 $25,410 - $44,130	-3,000 Closed	0 $0
Q3 2018 Nov 07, 2018	SELL	$13.7 - $17.12 $17,577 - $21,964	-1,283 Reduced 29.96%	3,000 $43,000
Q2 2018 Aug 10, 2018	BUY	$14.63 - $19.19 $41,695 - $54,691	2,850 Added 198.88%	4,283 $69,000
Q1 2018 May 11, 2018	BUY	$16.06 - $25.35 $16,589 - $26,186	1,033 Added 258.25%	1,433 $23,000
Q4 2017 Jan 17, 2018	BUY	$10.51 - $17.22 $1,051 - $1,722	100 Added 33.33%	400 $6,000
Q3 2017 Oct 17, 2017	BUY	$10.14 - $14.85 $3,042 - $4,455	300	300 $4,000

27.3M

Ticker GLYC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,423,900
Market Cap $15.2M
Description
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.